Use of normal tissue complication probability models in the clinic.
Lawrence B. Marks,Ellen Yorke,Andrew Jackson,Randall K. Ten Haken,Louis S. Constine,Avraham Eisbruch,Søren M. Bentzen,Jiho Nam,Joseph O. Deasy +8 more
TLDR
The Quantitative Analysis of Normal Tissue Effects in the Clinic (QUANTEC) review summarizes the currently available three-dimensional dose/volume/outcome data to update and refine the normal tissue dose/ volume tolerance guidelines provided by the classic Emami et al. paper published in 1991.Abstract:
The Quantitative Analysis of Normal Tissue Effects in the Clinic (QUANTEC) review summarizes the currently available three-dimensional dose/volume/outcome data to update and refine the normal tissue dose/volume tolerance guidelines provided by the classic Emami et al. paper published in 1991. A "clinician's view" on using the QUANTEC information in a responsible manner is presented along with a description of the most commonly used normal tissue complication probability (NTCP) models. A summary of organ-specific dose/volume/outcome data, based on the QUANTEC reviews, is included.read more
Citations
More filters
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines
TL;DR: Lymphedema is a common complication after treatment for breast cancer and factors associated with increased risk of lymphedEMA include extent of axillary surgery, axillary radiation, infection, and patient obesity.
Journal ArticleDOI
ICRP PUBLICATION 118: ICRP Statement on Tissue Reactions and Early and Late Effects of Radiation in Normal Tissues and Organs – Threshold Doses for Tissue Reactions in a Radiation Protection Context
F A Stewart,A V Akleyev,Martin Hauer-Jensen,Jolyon H Hendry,N J Kleiman,Thomas J. MacVittie,B M Aleman,Angela B. Edgar,K Mabuchi,C R Muirhead,Roy E. Shore,William Wallace +11 more
TL;DR: Estimates of ‘practical’ threshold doses for tissue injury defined at the level of 1% incidence are provided and it appears that the rate of dose delivery does not modify the low incidence for reactions manifesting very late after low total doses, particularly for cataracts and circulatory disease.
ICRP statement on tissue reactions and early and late effects of radiation in normal tissues and organs -- threshold doses for tissue reactions in a radiation protection context
C. H. Clement,F. A. Stewart +1 more
TL;DR: In this paper, the authors present a statement on the early and late effects of ionising radiation in normal tumor and kidney responses to irradiation, as well as some modifications of normal tumor response.
Journal ArticleDOI
Impact of Intensity-Modulated Radiation Therapy Technique for Locally Advanced Non–Small-Cell Lung Cancer: A Secondary Analysis of the NRG Oncology RTOG 0617 Randomized Clinical Trial
Stephen G. Chun,Chen Hu,Hak Choy,R.U. Komaki,Robert Timmerman,Steven E. Schild,Jeffrey A. Bogart,Michael C. Dobelbower,Walter Bosch,James M. Galvin,V.S. Kavadi,Samir Narayan,Puneeth Iyengar,Clifford G. Robinson,Raymond B. Wynn,Adam Raben,Mark E. Augspurger,Robert MacRae,Rebecca Paulus,Jeffrey D. Bradley +19 more
TL;DR: IMRT was associated with lower rates of severe pneumonitis and cardiac doses in NRG Oncology clinical trial RTOG 0617, which supports routine use of IMRT for locally advanced NSCLC.
Journal ArticleDOI
Pelvic normal tissue contouring guidelines for radiation therapy: A radiation therapy oncology group consensus panel atlas
H. Joseph Barthold,Elizabeth O'Meara,Walter Bosch,Issam El Naqa,R. Al-Lozi,Seth A. Rosenthal,Colleen A. Lawton,W. Robert Lee,Howard M. Sandler,Anthony L. Zietman,Robert J. Myerson,Laura A. Dawson,Christopher G. Willett,Lisa A. Kachnic,Anuja Jhingran,Lorraine Portelance,J. Ryu,William Small,David K. Gaffney,Akila N. Viswanathan,Jeff M. Michalski +20 more
TL;DR: Consensus guidelines for pelvic normal tissue contouring were reached and are available as a CT image atlas on the RTOG Web site, which will allow uniformity in defining normal tissues for clinical trials delivering pelvic radiation and will facilitate future normal tissue complication research.
References
More filters
Journal ArticleDOI
Tolerance of normal tissue to therapeutic irradiation.
B. Emami,John Lyman,A.P. Brown,Lawrence R. Coia,Michael Goitein,John E. Munzenrider,Brenda Shank,Lawrence J. Solin,Michael F. Wesson +8 more
TL;DR: The updated information on tolerance of normal tissues of concern in the protocols of this contract, based on available data, is presented, with a special emphasis on partial volume effects.
Journal ArticleDOI
CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment.
Andy Trotti,A. Dimitrios Colevas,Ann Setser,Valerie W. Rusch,David P. Jaques,Volker Budach,Corey J. Langer,Barbara A. Murphy,Richard Cumberlin,C. Norman Coleman,Philip Rubin +10 more
TL;DR: Recent progress in the evolution of adverse effects grading systems is updated and the development of CTCAE v3.0 is reviewed, which represents an international collaboration and consensus of the oncology research community.
Journal ArticleDOI
Fitting of normal tissue tolerance data to an analytic function
TL;DR: A four-parameter empirical model has been applied to a compilation of clinical tolerance data developed by Emami et al. and the four parameters to characterize the tissue response have been determined and graphical representations of the derived probability distributions are presented.
Journal ArticleDOI
Clinical dose-volume histogram analysis for pneumonitis after 3D treatment for non-small cell lung cancer (NSCLC)
Mary V. Graham,James A. Purdy,Bahman Emami,William B. Harms,Walter R. Bosch,Mary Ann Lockett,Carlos A. Perez +6 more
TL;DR: The V20 from the total lung DVH is a useful parameter easily obtained from most 3D treatment planning systems and may be useful in comparing competing treatment plans to evaluate the risk of pneumonitis for individual patient treatment.
Journal ArticleDOI
Complication Probability as Assessed from Dose-Volume Histograms
TL;DR: A recursive algorithm which uses tolerance dose data has been written and can be applied to arbitrary dose-volume histograms to estimate the complication probability.